Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.

Farshchi A, Aghili R, Oskuee M, Rashed M, Noshad S, Kebriaeezadeh A, Kia M, Esteghamati A.

BMC Endocr Disord. 2016 Jun 9;16(1):35. doi: 10.1186/s12902-016-0116-8.

2.

Insulin Aspart in the Management of Diabetes Mellitus: 15 Years of Clinical Experience.

Hermansen K, Bohl M, Schioldan AG.

Drugs. 2016 Jan;76(1):41-74. doi: 10.1007/s40265-015-0500-0. Review.

3.

Present status of insulin therapy for type 2 diabetes treated by general practitioners and diabetes specialists in Japan: Third report of a cross-sectional survey of 15,652 patients.

Arai K, Takai M, Hirao K, Matsuba I, Matoba K, Takeda H, Kanamori A, Yamauchi M, Mori H, Terauchi Y.

J Diabetes Investig. 2012 Aug 20;3(4):396-401. doi: 10.1111/j.2040-1124.2012.00198.x.

4.

Optimal management of type 2 diabetes in patients with increased risk of hypoglycemia.

Anderson M, Powell J, Campbell KM, Taylor JR.

Diabetes Metab Syndr Obes. 2014 Mar 6;7:85-94. doi: 10.2147/DMSO.S48896. eCollection 2014. Review.

5.

Role of diabetes in the development of acute respiratory distress syndrome.

Yu S, Christiani DC, Thompson BT, Bajwa EK, Gong MN.

Crit Care Med. 2013 Dec;41(12):2720-32. doi: 10.1097/CCM.0b013e318298a2eb.

6.

Safety and effectiveness of bolus insulin aspart in people with type 2 diabetes: a1chieve sub-analysis.

Randeree H, Liebl A, Hajjaji I, Khamseh M, Zajdenverg L, Chen JW, Haddad J.

Diabetes Ther. 2013 Jun;4(1):153-66. doi: 10.1007/s13300-013-0026-y. Epub 2013 Jun 12.

7.

Safety and effectiveness of insulin aspart in Basal-bolus regimens regardless of age: a1chieve study results.

Latif ZA, Hussein Z, Litwak L, El Naggar N, Chen JW, Soewondo P.

Diabetes Ther. 2013 Jun;4(1):103-18. doi: 10.1007/s13300-013-0023-1. Epub 2013 May 14.

8.

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes.

Hod M, Mathiesen ER, Jovanovič L, McCance DR, Ivanisevic M, Durán-Garcia S, Brøndsted L, Nazeri A, Damm P.

J Matern Fetal Neonatal Med. 2014 Jan;27(1):7-13. doi: 10.3109/14767058.2013.799650. Epub 2013 Jun 5.

9.

Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus.

Heller S, Bode B, Kozlovski P, Svendsen AL.

J Diabetes. 2013 Dec;5(4):482-91. doi: 10.1111/1753-0407.12060. Epub 2013 May 7.

10.

Rapid-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes.

Canadian Agency for Drugs and Technologies in Health (CADTH).

CADTH Technol Overv. 2010;1(1):e0110. Epub 2010 Mar 1. No abstract available.

11.

Uncovering undetected hypoglycemic events.

Unger J.

Diabetes Metab Syndr Obes. 2012;5:57-74. doi: 10.2147/DMSO.S29367. Epub 2012 Mar 8.

13.

Insulin glulisine in the management of diabetes.

Yamada S.

Diabetes Metab Syndr Obes. 2009 Jul 7;2:111-5.

14.

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus.

Lih A, Hibbert E, Wong T, Girgis CM, Garg N, Carter JN.

Diabetes Metab Syndr Obes. 2010 Nov 26;3:403-12. doi: 10.2147/DMSOTT.S5116.

15.

Hypoglycemia in type 1 diabetic pregnancy: role of preconception insulin aspart treatment in a randomized study.

Heller S, Damm P, Mersebach H, Skjøth TV, Kaaja R, Hod M, Durán-García S, McCance D, Mathiesen ER.

Diabetes Care. 2010 Mar;33(3):473-7. doi: 10.2337/dc09-1605. Epub 2009 Dec 10.

16.

An estimation of the long-term clinical and economic benefits of insulin lispro in Type 1 diabetes in the UK.

Pratoomsoot C, Smith HT, Kalsekar A, Boye KS, Arellano J, Valentine WJ.

Diabet Med. 2009 Aug;26(8):803-14. doi: 10.1111/j.1464-5491.2009.02775.x. Review.

17.

Use of short-acting insulin aspart in managing older people with diabetes.

Marouf E, Sinclair AJ.

Clin Interv Aging. 2009;4:187-90. Epub 2009 May 14. Review.

18.

Biphasic insulin aspart 30/70: pharmacokinetics and pharmacodynamics compared with once-daily biphasic human insulin and Basal-bolus therapy.

Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ.

Diabetes Care. 2009 Aug;32(8):1431-3. doi: 10.2337/dc09-0097. Epub 2009 Jun 1.

19.

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis.

Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H.

CMAJ. 2009 Feb 17;180(4):385-97. doi: 10.1503/cmaj.081041.

20.

Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Hartman I.

Clin Med Res. 2008 Sep;6(2):54-67. doi: 10.3121/cmr.2008.793. Epub 2008 Sep 18. Review.

Supplemental Content

Support Center